Study: Confirmatory Prostate Biopsies Still Needed Despite Upfront MRI
New findings challenge recommendations from the European Association of Urology.
Diagnosis & Disease Information
Prostate Cancer Grade Migration Documented
Grade group 1 prostate cancers declined as a proportion of all prostate cancers.
Clinical Biomarkers of Lupus Nephritis Activity Unreliable
Proteinuria and estimated glomerular filtration rate cannot accurately distinguish between ongoing inflammatory injury and chronic kidney damage in lupus nephritis, investigators pointed out.
Diabetes Linked With Major Bleeding Complications After Renal Biopsy
Diabetes is a possible risk factor for major bleeding complications after percutaneous renal biopsy, according to investigators.
Study: Prostate Cancer Surgery Without Prior Biopsy Possible
In a series of 25 men, radiographic evidence correctly predicted significant prostate cancer in all patients on final pathology.
Procedures to Diagnose Cancer, New Cancer Diagnoses Decreased in 2020
Colonoscopies decreased by 45% in 2020 compared with averages in 2018 through 2019; 29% decrease seen in prostate biopsies
Risk for High-Grade Prostate Cancer Is Low Following Negative MRI, Biopsy
In a study, no patient was diagnosed with high-grade prostate cancer within 3 years following a negative prostate MRI and negative systematic prostate biopsy.
MRI Results Might Permit Sparing of the Transitional Zone During Prostate Biopsy
Compared with peripheral zone prostate cancers, transitional zone cancers are less prevalent and tend to have more favorable pathological characteristics.
Promising Developments That May Improve Lupus Nephritis Management
Recent approval of new drugs for lupus nephritis and promising therapies on the horizon bode well for the care of patients with the kidney disorder.
Investigators: Consider 5-ARI Use When Deciding on Prostate Biopsy
At prostate cancer diagnosis, clinical T stage was significantly higher among 5-ARI users compared with nonusers.
- Loading...
Loading...
Next post in AUA2021 Virtual Experience
Loading... 
Loading...